Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.
How it helps
Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.
With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.
How it works
Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.
Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.
Scrips global team of journalists span key markets around the clock
Get exclusive access to accurate data, timely insights and trusted analysis that delivers to gain competitive advantage
Access interviews with leading decision makers, industry experts and thought leaders, across the industry.
Put your questions about any of our news stories, data and analysis to our expert journalists and analysts.
Scrip
By Viren Mehta 20 Jul 2018
With money pouring into biopharma in China, and regulatory reforms favoring market growth and R&D speed, western firms should watch their backs, warns Viren Mehta, founding partner of Mehta Partners LLC.
Topic Policy and regulation
Scrip
By Jo Shorthouse 20 Jul 2018
Pharma has been busy making deals this year, while the political winds of change swirl overhead, as our infographic shows. Companies both big and small have been merging to carve out therapeutic niches, return value to shareholders, and position themselves for the next wave of innovation and change.
Topic Business strategies
Scrip
By Emily Hayes 18 Jul 2018
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.
Topic Obesity Clinical trials
Scrip
By Jessica Merrill 18 Jul 2018
J&J told investors to anticipate negative net drug pricing of 4%-6% across its portfolio in 2018, following a 4.6% negative impact in 2017. CEO Alex Gorsky also cautioned against changing drug pricing policy too quickly.
Topic Policy and regulation
Scrip
By Jung Won Shin 13 Jul 2018
South Korean financial authorities conclude Samsung BioLogics violated accounting standards by omitting certain information on its joint venture agreement with Biogen from public disclosures, and have ordered further investigation of a corporate governance decision on the handling in accounts of the JV, Samsung Bioepis. The latest ruling in the prolonged affair could hurt the credibility and business of Samsung BioLogics going forward, although the firm maintains it has done nothing improper.
Topic Policy and regulation
Scrip
By Jessica Merrill 13 Jul 2018
Mylan has priced its biosimilar version of pegfilgrastim at a 33% discount to Amgen's WAC for Neulasta, steeper than the 15% discount Pfizer initially offered for Inflectra. The commercial outcome for Fulphila could set the tone for future US biosimilars, which have yet to take off.
Scrip
By Brian Yang 11 Jul 2018
Bagging a $200m box office in its opening week in China, "Dying to Survive" is a sentimental movie about a Chinese businessman selling cancer drugs smuggled from India but unapproved in China that sees his life taking a drastic turn, from convicted felon to a Robin Hood-like hero as he helps those in need. The Chinese film authority’s clearance for the screening of the movie and the smash success signal three key messages about the future potential direction of oncology drugs in the country.
Topic Cancer
Scrip
By Jessica Merrill 11 Jul 2018
After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.
Topic Policy and regulation
Scrip
By Emily Hayes 06 Jul 2018
With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.
Topic Cancer
Scrip
By Mike Ward 06 Jul 2018
Former UK science minister Lord Drayson explains to Scrip his plans for Sensyne Health, an Oxford, UK-based AI-focused healthcare technology company, to go public after securing a second deal with an NHS Foundation Trust while seeking big pharma research collaborations.
Topic Business strategies
Scrip
By Neena Brizmohun 28 Jun 2018
With Novartis’s and Kite’s CAR T-cell therapies both expected to gain recommendations for pan-EU approval this week, discounts will need to be negotiated for these new treatments to reach the markets in Europe.
Topic Cell and gene therapy
Scrip
By Joseph Haas 28 Jun 2018
The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.
Topic Alzheimers
Scrip
By Emily Hayes 21 Jun 2018
Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.
Topic Diabetes
Scrip
By Eleanor Malone 21 Jun 2018
Emerging Company Profile: ENYO Pharma has been around for barely four years, but it is already advancing its lead programs into Phase II trials in hepatitis B and NASH, and anticipates many more uses for its virology-based platform that will go way beyond treating virus infections.
Topic Company analysis Hepatitis B
Scrip
By Brian Yang 14 Jun 2018
Recent biotech investment deals involving WuXi, Oncologie and Siranomics show Chinese investors are becoming increasingly bold and savvy in betting on innovative assets both inside and outside the country.
Topic BioPharmaceutical
Scrip
19 Jul 2018
Scrip
19 Jul 2018
Scrip
19 Jul 2018
Scrip
19 Jul 2018
Scrip
19 Jul 2018
Scrip
18 Jul 2018
Scrip
18 Jul 2018
Scrip
18 Jul 2018
Scrip
18 Jul 2018
Scrip
18 Jul 2018
Scrip
18 Jul 2018
Scrip
17 Jul 2018
Scrip
17 Jul 2018
Scrip
17 Jul 2018
Scrip
17 Jul 2018
UK
+31 year(s) experience
USA
Denise specializes in
+27 year(s) experience
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
From discovery to patent expiry, and coverage spanning both ethical and generic drugs, Medtrack has you covered. Stay current on key financing, drug and biologics development and drug manufacturing information, all with a single tool.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Keep up to date